Description:Birinapant is a small-molecule compound classified as a dual inhibitor of the cellular inhibitors of apoptosis proteins (IAPs), specifically targeting IAP1 and IAP2. It is primarily investigated for its potential in cancer therapy, particularly in enhancing the efficacy of other anticancer agents by promoting apoptosis in tumor cells. Birinapant functions by disrupting the IAPs' ability to inhibit caspases, which are crucial enzymes in the apoptotic pathway. This mechanism of action makes it a candidate for combination therapies, especially in malignancies resistant to conventional treatments. The compound is typically administered via intravenous injection and has been evaluated in various clinical trials for its safety and effectiveness in treating different types of cancer. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are essential for understanding its therapeutic potential and optimizing dosing regimens. Overall, Birinapant represents a promising approach in the field of targeted cancer therapies, aiming to overcome resistance mechanisms in tumor cells.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1…](https://static.cymitquimica.com/products/IN/thumb/DA000QRV.jpg)
